BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting
First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg
Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05,
BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive
BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes
Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins,
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indications in immunology
